Leishmaniasis: Focus on the design of nanoparticulate vaccine delivery systems

Expert Review of Vaccines

Volumn 11, Issue 1, 2012, Pages 69-86

  Doroud, Delaram ^a   Rafati, Sima ^a  

^a PASTEUR INSTITUTE OF IRAN   (Iran)

Author keywords

adjuvant; delivery system; leishmaniasis; nanoparticle; solid lipid nanoparticles; vaccination

Indexed keywords

IMMUNOLOGICAL ADJUVANT; LEISHMANIA VACCINE; MONTANIDE ISA 720; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 12; SOLID LIPID NANOPARTICLE; UNCLASSIFIED DRUG;

DRUG DELIVERY SYSTEM; DRUG FORMULATION; HUMAN; IMMUNE RESPONSE; LEISHMANIA; LEISHMANIASIS; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; LEISHMANIA; LEISHMANIASIS; LEISHMANIASIS VACCINES; NANOPARTICLES;

EID: 83155164597     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.11.166     Document Type: Review

References (152)

1. Sharma U, Singh S. Immunobiology of leishmaniasis. Indian J. Exp. Biol. 47(6), 412-423 (2009).
2. Desjeux P. Leishmaniasis: current situation and new perspective. Comp. Immunol. Microbiol. Infect. Dis. 27, 305-318 (2004). (Pubitemid 38842803)
3. Costa CH, Peters NC, Maruyama SR, de Brito EC, Santos IKF. Vaccines for the leishmaniases: proposals for a research agenda. PLoS Neg. Trop. Dis. 5(3), e943 (2011).
4. Desjeux P. Human leishmaniases: epidemiology and public health aspects. World Health Stat. 45, 267-275 (1992).
5. Desjeux P. The increase in risk factors for leishmaniasis worldwide. Trans. R. Soc. Trop. Med. Hyg. 95, 239-243 (2001). (Pubitemid 33713068)
6. Desjeux P. Leishmaniasis. Nat. Rev. Microbiol. 2, 692 (2004).
7. Desjeux P, Alvar J. Leishmania/HIV co-infection: epidemiology in Europe. Ann. Trop. Med. Parasitol. 97(1), 3-15 (2003).
8. Alvar J. The relationship between leishmaniasis and AIDS: the second 10 years. Clin. Microbiol. Rev. 21, 334-359 (2008). (Pubitemid 351555511)
9. Ezra N, Ochoa MT, Craft N. Human immunodeficiency virus and leishmaniasis. J. Glob. Infect. Dis. 2(3), 248-257 (2010).
10. Murray HW, Berman JD, Davies CR, Saravia NG. Advances in leishmaniasis. Lancet 366(9496), 1561-1577 (2005). (Pubitemid 41540115)
11. Herwaldt BL. Leishmaniasis. Lancet 354(9185), 1191-1199 (1999). (Pubitemid 29460458)
12. Reithinger R, Dujardin JC, Louzir H et al. Cutaneous leishmaniasis. Lancet 7, 581-596 (2007). (Pubitemid 47277438)
13. Bravo F, Sanchez MR. New and re-emerging cutaneous infectious diseases in Latin America and other geographic areas. Dermatol. Clin. 21(4), 655-668 (2003). (Pubitemid 38005080)
14. James WD, Berger TG et al. Andrews' Diseases of the Skin: Clinical Dermatology. Saunders Elsevier, ON, Canada (2006).
15. Ganguly S, Das NK, Barbhuiya JN, Chatterjee M. Post-kala-azar dermal leishmaniasis - an overview. Int. J. Dermatol. 49(8), 921-931 (2010).
16. Dereure J, El-Safi SH, Bucheton B et al. Visceral leishmaniasis in eastern Sudan: parasite identification in humans and dogs host-parasite relationships. Microbes Infect. 5(12), 1103-1108 (2003). (Pubitemid 37211471)
17. Modabber F. Leishmaniasis vaccines: past, present and future. Int. J. Antimicrob. Agents 36(1), S58-S61 (2010).
18. Okwor I, Uzonna JE. Immunotherapy as a strategy for treatment of leishmaniasis: a review of the literature. Immunotherapy 1(5), 765-776 (2009).
19. Khamesipour A, Dowlati Y, Asilian A et al. Leishmanization: use of an old method for evaluation of candidate vaccines against leishmaniasis. Vaccine 23(28), 3642-3648 (2005). (Pubitemid 40692409)
20. Noazin S, Khamesipour A, Moulton LH et al. Efficacy of killed whole-parasite vaccines in the prevention of leishmaniasis: a meta-analysis. Vaccine 27(35), 4747-4753 (2009).
21. Bertholet S, Goto Y, Carter L et al. Optimized subunit vaccine protects against experimental leishmaniasis. Vaccine 27(50), 7036-7045 (2009).
22. Scott P, Pearce E, Natovitz P, Sher A. Vaccination against cutaneous leishmaniasis in a murine model. II. Immunologic properties of protective and nonprotective subfractions of soluble promastigote extract. J. Immunol. 139(9), 3118-3125 (1987). (Pubitemid 17157488)
23. Ramos I, Alonso A, Marcen JM et al. Heterologous prime-boost vaccination with a non-replicative vaccinia recombinant vector expressing LACK confers protection against canine visceral leishmaniasis with a predominant Th1-specific immune response. Vaccine 26(3), 333-344 (2008).
24. Dunning N. Leishmania vaccines: from leishmanization to the era of DNA technology. Biosci. Horizons 2(1), 73-82 (2009).
25. Daneshvar H, Molaei MM, Kamiabi H, Burchmore R, Hagan P, Stephen Phillips R. Gentamicin-attenuated Leishmania infantum: cellular immunity production and protection of dogs against experimental canine leishmaniasis. Parasite Immunol. 32(11-12), 722-730 (2010).
26. Nagill R, Kaur S. Vaccine candidates for leishmaniasis: a review. Int. Immunopharmacol. 11(10), 1464-1488 (2011).
27. Mizbani A, Taheri T, Zahedifard F et al. Recombinant Leishmania tarentolae expressing the A2 virulence gene as a novel candidate vaccine against visceral leishmaniasis. Vaccine 28(1), 53-62 (2009).
28. Breton M, Tremblay MJ, Ouellette M et al. Live nonpathogenic parasitic vector as a candidate vaccine against visceral leishmaniasis. Infect. Immun. 73(10), 6372-6382 (2005). (Pubitemid 41368798)
29. Kwissa M, Kasturi SP, Pulendran B. The science of adjuvants. Expert. Rev. Vaccines 6(5), 673-684 (2007). (Pubitemid 47607845)
30. Zhu J, Yamane H, Paul WE. Differentiation of effector CD4 T cell populations. Annu. Rev. Immunol. 28, 445-489 (2010).
31. Sallusto F, Lanzavecchia A, Araki K, Ahmed R. From vaccines to memory and back. Immunity 33, 451-463 (2010).
32. Pulendran B, Ahmed R. Immunological mechanisms of vaccination. Nat. Immunol. 12(6), 509-517 (2011).
33. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol. 11, 373-384 (2010).
34. Demento SL, Siefert AL, Bandyopadhyay A, Sharp FA, Fahmy TM. Pathogen-associated molecular patterns on biomaterials: a paradigm for engineering new vaccines. Trends Biotechnol. 29(6), 294-306 (2011).
35. Miyaji EN, Carvalho E, Oliveira ML, Raw I, Ho PL. Trends in adjuvant development for vaccines: DAMPs and PAMPs as potential new adjuvants. Braz. J. Med. Biol. Res. 4(6), 500-513 (2011).
36. Schenten D, Medzhitov R. The control of adaptive immune responses by the innate immune system. Adv. Immunol. 109, 87-124 (2011).
37. Moresco EM, Lavine D, Beutler B. Toll-like receptors. Curr. Biol. 21(13), 488-493 (2011).
38. Geijtenbeek TB, Gringhuis SI. Signalling through C-type lectin receptors: shaping immune responses. Nat. Rev. Immunol. 9, 465-479 (2009).
39. Ting JP, Duncan JA, Lei Y. How the non inflammasome NLRs function in the innate immune system. Science 327, 286-290 (2010).
40. Onoguchi K, Yoneyama M, Fujita T. Retinoic acid-inducible gene-I-like receptors. J. Interferon Cytokine Res. 31(1), 27-31 (2011).
41. Gallego C, Golenbock D, Gomez MA, Saravia NG. Toll-like receptors participate in macrophage activation and intracellular control of Leishmania (Viannia) panamensis. Infect. Immun. 79(7), 2871-2879 (2011).
42. Silva GK, Gutierrez FR, Guedes PM et al. Cutting edge: nucleotide-binding oligomerization domain 1-dependent responses account for murine resistance against Trypanosoma cruzi infection. J. Immunol. 184(3), 1148-1152 (2010).
43. Sharp F, Ruane D, Claas B et al. Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome. Proc. Natl Acad. Sci USA 106, 870-875 (2009).
44. Pulendran B, Ahmed R. Translating innate immunity into immunological memory: implications for vaccine development. Cell 124, 849-863 (2006). (Pubitemid 43261457)
45. Coffman RL, Sher A, Seder RA. Vaccine adjuvants: putting innate immunity to work. Immunity 33, 492-503 (2010).
46. Steinman RM. Dendritic cells in vivo: a key target for a new vaccine science. Immunity 29, 319-324 (2008).
47. Pulendran B, Li S, Nakaya HI. Systems vaccinology. Immunity 33, 516-529 (2010).
48. McKee AS, Macleod MK, Kappler JW, Marrack P. Immune mechanisms of protection: can adjuvants rise to the challenge? BMC Biol. 8, 37 (2010).
49. Pajtasz-Piasecka E, Indrová M. Dendritic cell-based vaccines for the therapy of experimental tumors. Immunotherapy 2(2), 257-268 (2010).
50. Gerlach C, van Heijst JW, Schumacher TN. The descent of memory T cells. Ann. NY Acad. Sci. 1217, 139-153 (2011).
51. Bhowmick S, Ali N. Recent developments in leishmaniasis vaccine delivery systems. Expert. Opin. Drug Deliv. 5(7), 789-803 (2008).
52. Mutiso M, Macharia JC, Gicheru MM. A review of adjuvants for Leishmania vaccine candidates. J. Biomed. Res. 24(1), 16-25 (2010).
53. Afonso LC, Scharton TM, Vieira LQ et al. The adjuvant effect of interleukin-12 in a vaccine against Leishmania major. Science 263(5144), 235-237 (1994). (Pubitemid 24067932)
54. Gicheru MM, Olobo JO, Anjili CO et al. Vervet monkeys vaccinated with killed Leishmania major parasites and interleukin-12 develop a type 1 immune response but are not protected against challenge infection. Infect. Immun. 69(1), 245-251 (2001). (Pubitemid 32038320)
55. Skeiky YA, Coler RN, Brannon M et al. Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL adjuvant. Vaccine 20(27-28), 3292-3303 (2002). (Pubitemid 35245813)
56. Badaro R, Lobo I, Nakatani M et al. Successful use of a defined antigen/ GM-CSF adjuvant vaccine to treat mucosal Leishmaniasis refractory to antimony: A case report. Braz. J. Infect. Dis. 5(4), 223-232 (2001).
57. Badaró R, Nascimento C, Carvalho JS et al. Recombinant human granulocyte- macrophage colony-stimulating factor reverses neutropenia and reduces secondary infections in visceral leishmaniasis. J. Infect. Dis. 170(2), 413-418 (1994). (Pubitemid 24226372)
58. Milstien JB, Gibson JJ. Quality control of BCG vaccine by WHO: a review of factors that may influences vaccine effectiveness and safety. WHO Bull. OMS 68, 93-108 (1990). (Pubitemid 20153776)
59. Simila S, Liedes E, Kinnunen P. Sternal abscess as a complication of BCG reactivation. Tubercle 69, 67-69 (1988). (Pubitemid 18064563)
60. Oliveira GA, Wetzel K, Calvo-Calle JM et al. Safety and enhanced immunogenicity of a hepatitis B core particle Plasmodium falciparum malaria vaccine formulated in adjuvant Montanide ISA 720 in a Phase I trial. Infect. Immun. 73(6), 3587-3597 (2005). (Pubitemid 40745903)
61. Collins WE, Barnwell JW, Sullivan JS et al. Assessment of transmission-blocking activity of candidate Pvs25 vaccine using gametocytes from chimpanzees. Am. J. Trop. Med. Hyg. 74(2), 215-221 (2006). (Pubitemid 46774330)
62. Rafati S, Nakhaee A, Taheri T et al. Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum. Vaccine 23(28), 3716-3725 (2005). (Pubitemid 40692418)
63. Scheibner V. Adverse effects of adjuvants in vaccines. Exp. Mol. Pathol. 8, 1-2 (2000).
64. Gurunathan S, Prussin C, Sacks DL, Seder RA. Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection. Nat. Med. 4(12), 1409-1415 (1998). (Pubitemid 28553464)
65. Kenney RT, Sacks DL, Sypek JP et al. Protective immunity using recombinant human IL-12 and alum as adjuvants in a primate model of cutaneous leishmaniasis. J. Immunol. 163(8), 4481-4488 (1999). (Pubitemid 29474517)
66. Misra A, Dube A, Srivastava B et al. Successful vaccination against Leishmania donovani infection in Indian langur using alum-precipitated autoclaved Leishmania major with BCG. Vaccine 19(25-26), 3485-3492 (2001). (Pubitemid 32710300)
67. Lindblad EB. Aluminium compounds for use in vaccines. Immunol. Cell Biol. 82(5), 497-505 (2004). (Pubitemid 39421059)
68. Reed SG, Coler RN, Campos-Neto A. Development of a leishmaniasis vaccine: the importance of MPL. Expert. Rev. Vaccines 2(2), 239-252 (2003). (Pubitemid 36559929)
69. Chakravarty J, Kumar S, Trivedi S et al. A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of visceral leishmaniasis. Vaccine 29(19), 3531-3537 (2011).
70. Coler RN, Goto Y, Bogatzki L, Raman V, Reed SG. Leish-111f, a recombinant polyprotein vaccine that protects against visceral Leishmaniasis by elicitation of CD4+ T cells. Infect. Immun. 75(9), 4648-4654 (2007).
71. Verthelyi D, Klinman DM. Immunoregulatory activity of CpG oligonucleotides in humans and nonhuman primates. Clin. Immunol. 109(1), 64-71 (2003). (Pubitemid 37324743)
72. Klinman DM, Klaschik S, Sato T, Tross D. CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases. Adv. Drug Deliv. Rev. 61(3), 248-255 (2009).
73. Bolhassani A, Safaiyan SH, Rafati S. Improvement of different vaccine delivery systems for cancer therapy. Mol. Cancer 10, 3 (2011).
74. Rafati S, Ghaemimanesh F, Zahedifard F. Comparison of potential protection induced by three vaccination strategies (DNA/DNA, protein/protein and DNA/ protein) against Leishmania major infection using signal peptidase type I in BALB/c mice. Vaccine 24(16), 3290-3297 (2006).
75. Flynn B, Wang V, Sacks DL et al. Prevention and treatment of cutaneous leishmaniasis in primates by using synthetic type D/A oligodeoxynucleotides expressing CpG motifs. Infect. Immun. 73(8), 4948-4954 (2005). (Pubitemid 41105652)
76. Rhee EG, Mendez S, Shah JA et al. Vaccination with heat-killed Leishmania antigen or recombinant leishmanial protein and CpG oligodeoxynucleotides induces long-term memory CD4+ and CD8+ T cell responses and protection against Leishmania major infection. J. Exp. Med. 195(12), 1565-1573 (2002).
77. Quintilio W, Kubrusly FS, Iourtov D et al. Bordetella pertussis monophosphoryl lipid A as adjuvant for inactivated split virion influenza vaccine in mice. Vaccine 27(31), 4219-4224 (2009).
78. Champsi J, McMahon-Pratt D. Membrane glycoprotein M-2 protects against Leishmania amazonensis infection. Infect. Immun. 56(12), 3272-3279 (1988).
79. Handman E, Symons FM, Baldwin TM et al. Protective vaccination with promastigote surface antigen 2 from Leishmania major is mediated by a Th1 type of immune response. Infect. Immun. 63(11), 4261-4267 (1995).
80. Pandey R, Ahmad Z. Nanomedicine and experimental tuberculosis: facts, flaws, and future. Nanomedicine 7(3), 259-272 (2011).
81. Peek LJ, Middaugh CR, Berkland C. Nanotechnology in vaccine delivery. Adv. Drug Deliv Rev. 60, 915-928 (2008).
82. Van Rooijen N, Sanders A. The macrophage as target or obstacle in liposome-based targeting strategies. Int. J. Phar. 162(1-2), 45-50 (1998). (Pubitemid 28166089)
83. Burke B, Sumner S, Maitland N, Lewis CE. Macrophages in gene therapy: cellular delivery vehicles and in vivo targets. J. Leuk. Biol. 72(3) 417-428 (2002).
84. Espuelas S. Treatment and prevention of leishmaniasis. Gaz. Méd. Bahia. 79(3), 134-146 (2009).
85. Kreuter J. Drug targeting with nanoparticles. Eur. J. Drug Metab. Pharmacokinet. 19, 253-256 (1994). (Pubitemid 24331195)
86. Prijic S, Sersa G. Magnetic nanoparticles as targeted delivery systems in oncology. Radiol. Oncol. 45(1), 1-16 (2011).
87. O'Hagan DT, Singh M. Microparticles as vaccine adjuvants and delivery systems. Expert Rev. Vaccines 2(2), 269-283 (2003). (Pubitemid 36559931)
88. Muller RH, Keck CM. Challenges and solutions for the delivery of biotech drugs - a review of drug nanocrystal technology and lipid nanoparticles. J. Biotech. 113, 151-170 (2004). (Pubitemid 39237077)
89. Tafaghodi M, Eskandari M, Khamesipour A, Jaafari MR. Alginate microspheres encapsulated with autoclaved Leishmania major (ALM) and CpG-ODN induced partial protection and enhanced immune response against murine model of leishmaniasis. Exp. Parasitol. 129(2), 107-114 (2011).
90. Tafaghodi M, Eskandari M, Kharazizadeh M, Khamesipour A, Jaafari MR. Immunization against leishmaniasis by PLGA nanospheres loaded with an experimental autoclaved Leishmania major (ALM) and Quillaja saponins. Trop. Biomed. 27(3), 639-650 (2010).
91. Santos LE, Colhone MC, Daghastanli KR, Stabeli RG, Silva-Jardim I, Ciancaglini P. Lipid microspheres loaded with antigenic membrane proteins of the Leishmania amazonensis as a potential biotechnology application. J. Colloid. Interface Sci. 340(1), 112-118 (2009).
92. Doroud D, Zahedifard F, Vatanara A et al. C-terminal domain deletion enhances the protective activity of cpa/cpb loaded solid lipid nanoparticles against Leishmania major in BALB/c mice. PLoS Negl. Trop. Dis. 5(7), e1236 (2011).
93. Doroud D, Zahedifard F, Vatanara A et al. Delivery of a cocktail DNA vaccine encoding cysteine proteinases type I, II and III with solid lipid nanoparticles potentiate protective immunity against Leishmania major infection. J. Control. Release 153(2), 154-162 (2011).
94. Doroud D, Zahedifard F, Vatanara A, Najafabadi AR, Rafati S. Cysteine proteinase type I, encapsulated in solid lipid nanoparticles induces substantial protection against Leishmania major infection in C57BL/6 mice. Parasite Immunol. 33(6), 335-348 (2011).
95. Doroud D, Vatanara A, Zahedifard F et al. Cationic solid lipid nanoparticles loaded by cysteine proteinase genes as a novel anti-leishmaniasis DNA vaccine delivery system: characterization and in vitro evaluations. J. Pharm. Pharm. Sci. 13(3), 320-335 (2010).
96. Moghimi SM, Hunter AC. Recognition by macrophages and liver cells of opsonized phospholipid vesicles and phospholipid headgroups. Pharm. Res. 18(1), 1-8 (2001). (Pubitemid 32299615)
97. França A, Aggarwal P, Barsov EV, Kozlov SV, Dobrovolskaia MA, González- Fernández Á. Macrophage scavenger receptor A mediates the uptake of gold colloids by macrophages in vitro. Nanomedicine (Lond.) 6(7), 1175-1188 (2011).
98. Kelly C, Jefferies C, Cryan SA. Targeted Liposomal drug delivery to monocytes and macrophages. J. Drug Del. (2011) (In Press).
99. Aderem A, Underhill D. Mechanisms of phagocytosis in macrophages. Annu. Rev. Immunol. 17, 593-623 (1999). (Pubitemid 29241135)
100. Champion JA, Mitragotri S. Role of target geometry in phagocytosis. PNAS 103(13), 4930-4934 (2006).
101. Aderem A. How to eat something bigger than your head. Cell 110, 5-8 (2002). (Pubitemid 34874600)
102. Joshi MD, Müller RH. Lipid nanoparticles for parenteral delivery of actives. Eur. J. Pharm. Biopharm. 71, 161-172 (2009).
103. Brewer JM, Tetley L, Richmond J, Liew FY, Alexander J. Cellular immunology and immune regulation: lipid vesicle size determines the Th1 or Th2 response to entrapped antigen. J. Immunol. 161, 4000-4007 (1998). (Pubitemid 28468977)
104. Lincopan N, Espindolab NM, Vazb AJ, da Costa MH, Faquim-Mauroc E, Carmona-Ribeiro AM. Novel immunoadjuvants based on cationic lipid: preparation, characterization and activity in vivo. Vaccine 27(42), 5760-5771 (2009).
105. Fifis T, Gamvrellis A, Crimeen-Irwin B et al. Size-dependent immunogenicity: therapeutic and protective properties of nanovaccines against tumors. J. Immunol. 173, 3148-3173 (2004).
106. Brewer JM, Pollock KGJ, Tetley L, Russell DG. Vesicle size influences the trafficking, processing, and presentation of antigens in lipid vesicles. J. Immunol. 173, 6143-6150 (2004). (Pubitemid 39487771)
107. Chen HC, Sun B, Tran KK, Shen H. Effects of particle size on Toll-like receptor 9-mediated cytokine profiles. Biomaterials 32, 1731-1737 (2011).
108. Mayer A, Vadon M, Rinner B, Novak A, Wintersteiger R,Fröhlich E. The role of nanoparticle size in hemocompatibility. Toxicology 258(2-3), 139-147 (2009).
109. Göppert TM, Müller RH. Plasma protein adsorption of Tween 80- and poloxamer 188-stabilized solid lipid nanoparticles. J. Drug Target. 11(4), 225-231 (2003). (Pubitemid 37361968)
110. Mehnert W, Mader K. Solid lipid nanoparticles production, characterization and applications. Adv. Drug Del. Rev. 47, 165-196 (2001). (Pubitemid 32324113)
111. del Pozo-Rodríguez A, Delgado D, Solinis MA, Gascon AR, Pedraz JL. Solid lipid nanoparticles: formulation factors affecting cell transfection capacity. Int. J. Pharm. 339, 261-268 (2007). (Pubitemid 46977611)
112. Seeballuck F, Lawless E, Ashford MB, O'Driscoll CM. Stimulation of triglyceriderich lipoprotein secretion by polysorbate 80: in vitro and in vivo correlation using caco-2 cells and a cannulated rat intestinal lymphatic model. Pharm. Res. 21, 2320-2326 (2004). (Pubitemid 40568446)
113. Singh M, Briones M, Ott G, O'Hagan D. Cationic microparticles: a potent delivery system for DNA vaccines. Proc. Natl Acad. Sci. 97(8), 11-16 (2000).
114. Thiele L, Rothen-Rutishauser B, Jilek S, Wunderli-Allenspach H, Merkle HP, Walter E. Evaluation of particle uptake in human blood monocyte-derived cells in vitro. Does phagocytosis activity of dendritic cells measure up with macrophages? J. Control. Release 76, 59-71 (2001). (Pubitemid 32786885)
115. Vangasseri DP, Cui Z, Chen W, Hokey DA, Falo LD, Huang L. Immunostimulation of dendritic cells by cationic liposomes. Mol. Membr. Biol. 23(5), 385-395 (2006). (Pubitemid 44630022)
116. Yan W, Chen W, Huang L. Mechanism of adjuvant activity of cationic liposome: phosphorylation of a MAP kinase, ERK and induction of chemokines. Mol. Immunol. 44 (15), 3672-3681 (2007). (Pubitemid 46817670)
117. Kedmi R, Ben-Arie N, Peer D. The systemic toxicity of positively charged lipid nanoparticles and the role of Toll-like receptor 4 in immune activation. Biomaterials 31(26), 6867-6875 (2010).
118. Wasungu L, Hoekstra D. Cationic lipids, lipoplexes and intracellular delivery of genes. J. Control. Release 116(2), 255-264 (2006). (Pubitemid 44854274)
119. Nobs L, Buchegger F, Gurny R, Allémann E. Current methods for attaching targeting ligands to liposomes andnanoparticles. J. Pharm. Sci. 93(8), 1980-1992 (2004). (Pubitemid 39045480)
120. Shimizu Y, Takagi H, Nakayama T et al. Intraperitoneal immunization with oligomannose-coated liposome-entrapped soluble leishmanial antigen induces antigen-specific T-helper type immune response in BALB/c mice through uptake by peritoneal macrophages. Parasite Immunol. 29(5), 229-239 (2007). (Pubitemid 46596114)
121. Shimizu Y, Yamakami K, Gomi T et al. Protection against Leishmania major infection by oligomannose-coated liposomes. Bioorg. Med. Chem. 11(7), 1191-1195 (2003). (Pubitemid 36293515)
122. McConville MJ, Bacic A, Mitchell GF, Handman E. Lipophosphoglycan of Leishmania major that vaccinates against cutaneous leishmaniasis contains an alkylglycerophosphoinositol lipid anchor. Proc. Natl Acad. Sci. USA 84(24), 8941-8945 (1987).
123. Danesh-Bahreini MA, Shokri J, Samiei A, Kamali-Sarvestani E, Barzegar-Jalali M, Mohammadi-Samani S. Nanovaccine for leishmaniasis: preparation of chitosan nanoparticles containing Leishmania superoxide dismutase and evaluation of its immunogenicity in BALB/c mice. Int. J. Nanomed. 6, 835-842 (2011).
124. Henriquez FL, Campbell SA, Roberts CW, Mullen AB, Burchmore R, Carter KC. Vaccination with recombinant Leishmania donovani g-glutamylcysteine synthetase fusion protein protects against L. donovani infection. J. Parasitol. 96(5), 929-936 (2010).
125. Bhowmick S, Mazumdar T, Sinha R, Ali N. Comparison of liposome based antigen delivery systems for protection against Leishmania donovani. J. Control. Release 141, 199-207 (2010).
126. Ravindran R, Bhowmick S, Das A, Ali N. Comparison of BCG, MPL and cationic liposome adjuvant systems in leishmanial antigen vaccine formulations against murine visceral leishmaniasis. BMC Microbiol. 10, 181 (2010).
127. Badiee A, Jaafari MR, Khamesipour A et al. Enhancement of immune response and protection in BALB/c mice immunized with liposomal recombinant major surface glycoprotein of Leishmania (rgp63): the role of bilayer composition. Colloids Surf. B. Biointerfaces 74(1), 37-44 (2009).
128. Badiee A, Jaafari MR, Khamesipour A et al. The role of liposome charge on immune response generated in BALB/c mice immunized with recombinant major surface glycoprotein of Leishmania (rgp63). Experimental Parasitol. 121(4), 362-369 (2009).
129. Badiee A, Jaafari MR, Samiei A, Soroush D, Khamesipour A. Coencapsulation of CpG oligodeoxynucleotides with recombinant Leishmania major stress-inducible protein 1 in liposome enhances immune response and protection against leishmaniasis in immunized BALB/c mice. Clin. Vacc. Immunol. 15(4), 668-674 (2008). (Pubitemid 351967047)
130. Bhowmick S, Ravindran R, Ali N. gp63 in stable cationic liposomes confers sustained vaccine immunity to susceptible BALB/c mice infected with Leishmania donovani. Infect. Immun. 76(3), 1003-1015 (2008). (Pubitemid 351428060)
131. Gomez CS. In-vivo delivery of DNA vaccines using metallo-lipid nanoparticles. ETD Collection for University of Texas, El Paso, TX, USA (2008).
132. Jaafari MR, Ghafarian A, Farrokh-Gisour A et al. Immune response and protection assay of recombinant major surface glycoprotein of Leishmania (rgp63) reconstituted with liposomes in BALB/c mice. Vaccine 24(29-30), 5708-5717 (2006). (Pubitemid 43928184)
133. Mazumder S, Ravindran R, Banerjee A, Ali N. Non-coding pDNA bearing immunostimulatory sequences co-entrapped with leishmanial antigens in cationic liposomes elicits almost complete protection against experimental visceral leishmaniasis in BALB/c mice. Vaccine 25(52), 8771-8781 (2007). (Pubitemid 350192062)
134. Badiee A, Jaafari MR, Khamesipour A. Leishmania major: immune response in BALB/c mice immunized with stress-inducible protein 1 encapsulated in liposomes Exp. Parasitol. 115(2), 127-134 (2007). (Pubitemid 44820050)
135. Sharma SK, Dube A, Nadeem A et al. Non PC liposome entrapped promastigote antigens elicit parasite specific CD8+ and CD4+ T-cell immune response and protect hamsters against visceral leishmaniasis. Vaccine 24(11), 1800-1810 (2006). (Pubitemid 43238261)
136. Santos FR, Ferraz DB, Daghastanli KR, Ramalho-Pinto FJ, Ciancaglini P. Mimetic membrane system to carry multiple antigenic proteins from Leishmania amazonensis. J. Membr. Biol. 210(3), 173-181 (2006). (Pubitemid 44306222)
137. Mazumdar T, Anam K, Ali N. A mixed Th1/Th2 response elicited by a liposomal formulation of Leishmania vaccine instructs Th1 responses and resistance to Leishmania donovani in susceptible BALB/c mice. Vaccine 22(9-10), 1162-1171 (2004). (Pubitemid 38296659)
138. Afrin F, Rajesh R, Anam K, Gopinath M, Pal S, Ali N. Characterization of Leishmania donovani antigens encapsulated in liposomes that induce protective immunity in BALB/c mice. Infect. Immun. 70(12), 6697-6706 (2002). (Pubitemid 35387900)
139. Afrin F, Anam K, Ali N. Induction of partial protection against Leishmania donovani by promastigote antigens in negatively charged liposomes. J. Parasitol. 86(4), 730-735 (2000). (Pubitemid 30646586)
140. Afrin F, Ali N. Adjuvanticity and protective immunity elicited by Leishmania donovani antigens encapsulated in positively charged liposomes. Infect. Immun. 65(6), 2371-2377 (1997). (Pubitemid 27237322)
141. Lezama-Dávila CM. Vaccination of different strains of mice against cutaneous leishmaniosis: usefulness of membrane antigens encapsulated into liposomes by intraperitoneal and subcutaneous administration. Arch. Med. Res. 28(1), 47-53 (1997). (Pubitemid 27154002)
142. Yang DM, Rogers MV, Liew FY. Identification and characterization of host-protective T-cell epitopes of a major surface glycoprotein (gp63) from Leishmania major. Immunology 72(1), 3-9 (1991).
143. Kahl LP, Scott CA, Lelchuk R, Gregoriadis G, Liew FY. Vaccination against murine cutaneous leishmaniasis by using Leishmania major antigen/ liposomes. Optimization and assessment of the requirement for intravenous immunization. J. Immunol. 142(12), 4441-4449 (1989). (Pubitemid 19162338)
144. Russell DG, Alexander J. Effective immunization against cutaneous leishmaniasis with defined membrane antigens reconstituted into liposomes. J. Immunol. 140(4), 1274-1279 (1988). (Pubitemid 18096704)
145. Pal I, Ramsey JD. The role of the lymphatic system in vaccine trafficking and immune response. Adv. Drug Deliv. Rev. 63(10-11), 909-922 (2011).
146. Christensen D, Korsholm KS, Andersen P, Agger EM. Cationic liposomes as vaccine adjuvants. Expert Rev. Vaccines 10(4), 513-521 (2011).
147. Henriksen-Lacey M, Korsholm KS, Andersen P, Perrie Y, Christensen D. Liposomal vaccine delivery systems. Expert. Opin. Drug. Del. 8, 505-519 (2011).
148. Jesorka A, Orwar O. Liposomes: technologies and analytical applications. Ann. Rev. Anal. Chem. 1, 801-832 (2008).
149. Bhowmick S, Mazumdar T, Ali N. Vaccination route that induces transforming growth factor b production fails to elicit protective immunity against Leishmania donovani infection. Infect. Immun. 77, 1514-1523 (2004).
150. Rafati S, Zahedifard F, Nazgouee F. Prime-boost vaccination using cysteine proteinases types I and II of Leishmania infantum confers protective immunity in murine visceral leishmaniasis. Vaccine 24, 2169-2175 (2006). (Pubitemid 43255160)
151. Manolova V, Flace A, Bauer M, Schwarz K, Saudan P, Bachmann MF. Nanoparticles target distinct dendritic cell populations according to their size. Eur. J. Immunol. 38, 1404-1413 (2008).
152. Rafati S, Salmanian AH, Taheri T, Vafa M, Fasel N. A protective cocktail vaccine against murine cutaneous leishmaniasis with DNA encoding cysteine proteinases of Leishmania major. Vaccine 19, 3369-3375 (2001). (Pubitemid 32710285)